Premium
The impact of Cytochrome P450‐2D6 genotype on the use and interpretation of therapeutic drug monitoring in long‐stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice
Author(s) -
Mulder Hans,
Herder Anita,
Wilmink Frederik W.,
Tamminga Wim J.,
Belitser Svetlana V.,
Egberts Antoine C. G.
Publication year - 2006
Publication title -
pharmacoepidemiology and drug safety
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.023
H-Index - 96
eISSN - 1099-1557
pISSN - 1053-8569
DOI - 10.1002/pds.1173
Subject(s) - cyp2d6 , therapeutic drug monitoring , medicine , pharmacogenetics , therapeutic index , antidepressant , antipsychotic , pharmacology , clinical endpoint , genotype , drug , pharmacokinetics , psychiatry , schizophrenia (object oriented programming) , cytochrome p450 , randomized controlled trial , chemistry , biochemistry , metabolism , hippocampus , gene
Purpose This retrospective follow‐up study investigates whether cytochrome P450‐2D6 (CYP2D6) genotype explains variability in plasma concentrations of psychotropic drugs in daily psychiatric practice. Methods The study population consisted of 62 hospitalised psychiatric patients genotyped for CYP2D6. Primary endpoint was the normalised plasma concentration ratio which was defined as the [measured concentration]/[mean therapeutic concentration] allowing comparison of plasma concentrations of different substrates. Secondary endpoint was a plasma concentration above the therapeutic range. The determinant was CYP2D6 genotype classified as ultrarapid metaboliser (UM), extensive metaboliser (EM), intermediate metaboliser (IM), or poor metaboliser (PM). The relation between CYP2D6 genotype and the normalised plasma concentration ratio was assessed with a linear mixed‐effects model after adjustment for the Prescribed Daily Dose (PDD). The risk of having a plasma concentration above the therapeutic range was assessed with a logistic mixed‐effects model. Results For antidepressants, CYP2D6 genotype PM (1.68 (95%CI: 1.01–2.28)) and IM (1.09 (95%CI: 0.77–1.29)) were associated with higher normalised plasma concentration ratios of antidepressants compared to EMs (0.56 (95%CI: 0.26–0.74)). In addition, the risk of a plasma concentration above the therapeutic range was increased for PMs (OR 33.1 (95%CI: 2.0–544.6)) and IMs (OR 8.2 (95%CI: 1.1–60.3)) relative to EMs using antidepressants. CYP2D6 genotype could not clearly explain variability in plasma concentrations of antipsychotics possibly due to a low frequency of therapeutic drug monitoring (TDM) in antipsychotics primarily metabolised by CYP2D6 in daily psychiatric practice. Conclusions CYP2D6 genotype contributes to clinically relevant variability in plasma concentrations of antidepressants but probably not antipsychotics in daily clinical practice. Copyright © 2005 John Wiley & Sons, Ltd.